A pharmaceutical composition treating severe high-altitude diseases

A composition and high altitude sickness technology, which can be used in drug combinations, blood diseases, pharmaceutical formulations, etc., and can solve the problems of lack of severe altitude sickness and no reports of clinical application.

Inactive Publication Date: 2014-11-12
CHANGZHOU HI TECH DISTRICT MULTIPLE DIMENSION IND TECH INST
View PDF3 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Chinese patent application number 200310104871.X discloses that levocarnitine has the effect of preventing and treating altitude sickness, but there is no clini

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A pharmaceutical composition treating severe high-altitude diseases
  • A pharmaceutical composition treating severe high-altitude diseases
  • A pharmaceutical composition treating severe high-altitude diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Embodiment one: Observation of the effect of intravenous injection of levocarnitine and trimetazidine hydrochloride in different dose ratios on normal pressure hypoxia in mice

[0019] Trimetazidine hydrochloride: 0.75, 2.25, 4.5 mg / kg, approximately equivalent to human daily dose of 5, 15, 30 mg;

[0020] Levocarnitine: 450mg / kg, approximately equivalent to a daily human dose of 3g

[0021] Select 40 male mice, body weight 20±2g, randomly divide them into 4 groups according to body weight, 10 mice in each group, administer by tail vein injection of 10ml / kg, and give equal volume of normal saline to the blank control group, 1 time / day, for 7 consecutive days. 1 h after the last administration, put the mice in each group into a 160ml jar with 5g of soda lime added in advance, one for each bottle, and then smear the bottle cap with vaseline and seal it tightly. mouse survival time [Zheng Yue, Ji Yang. Animal models and anti-hypoxic drugs commonly used in anti-hypoxia ...

Embodiment 2

[0026] Embodiment two: Effects of levocarnitine and trimetazidine hydrochloride (200:1), injection administration, single and compound on acute cerebral hypoxia model in mice

[0027] 40 male Kunming mice were randomly divided into 4 groups: normal control group, levocarnitine 600mg / kg group, trimetazidine hydrochloride 3 mg / kg group, levocarnitine 600+trimetazidine hydrochloride 3mg / kg kg group, 10 rats in each group. 10ml / kg injection, the normal control group was given an equal volume of normal saline, once a day, for 7 consecutive days. One hour after the last administration, the mice were quickly decapitated from behind the ears, and the time from the decapitation to the cessation of gasping for breath was recorded immediately according to a stopwatch. The results are shown in Table 2.

[0028] Table 2 Effects of single and compound prescriptions on the acute cerebral hypoxia model in mice (n=10, ± S )

[0029]

[0030] Note: Compared with normal control group, ...

Embodiment 3

[0038] Embodiment three: Observation of the effect of levocarnitine and trimetazidine hydrochloride (200:1) on hypobaric hypoxia in rats

[0039]Set the dose of levocarnitine+trimetazidine hydrochloride to 600+3mg / kg.

[0040] Select 30 Wister rats, weighing 150g to 190g, and randomly divide them into 3 groups: normoxia control group: raise and collect materials in plain areas; acute hypoxia group: place animals in a hypobaric oxygen chamber, and the oxygen partial pressure in the chamber is 11.01 Kpa (approximately equivalent to the partial pressure of oxygen at an altitude of 5000m) after continuous decompression and hypoxia for 3 days, and then placed in a hypobaric oxygen chamber with an oxygen partial pressure of 13.25Kpa (approximately equivalent to the partial pressure of oxygen at an altitude of 4000m) to collect specimens [Zheng Yue, Ji Yang. Animal models and anti-hypoxic drugs commonly used in anti-hypoxia research. PLA Pharmaceutical Journal, 2010, 26 (2): 170~1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a pharmaceutical composition used for treating severe altitude sickness, characterized by a composition consisting of trimetazidine or pharmaceutically acceptable salt thereof and L-carnitine or derivative thereof or pharmaceutically acceptable salt thereof, and the weight ratio of the above being 1:200.

Description

technical field [0001] The invention relates to the field of pharmaceutical compositions, in particular to a pharmaceutical composition for treating severe altitude sickness. Background technique [0002] Severe altitude sickness is severe acute altitude sickness caused by severe acute altitude hypoxia, such as pulmonary edema, cerebral edema, and shock. [0003] The traditional treatment for severe altitude sickness is hyperbaric oxygen inhalation and symptomatic treatment (lowering pulmonary arterial pressure, intracranial pressure, etc.), tracheal intubation if necessary, continuous positive pressure ventilation and adequate oxygenation, and transfer to lowland for further treatment after the condition is stable And drug treatment, currently commonly used treatment drugs include painkillers such as aspirin, diuretics such as acetazolamide, furosemide, adrenocortical hormone drugs such as dexamethasone, various vitamins and aminophylline, etc. To use cardiac glycosides, s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/495A61P39/00A61P7/10A61P9/02A61K31/205
CPCA61K31/205A61K31/495A61P7/10A61P9/02A61P39/00A61K2300/00
Inventor 谢和兵李庆宜顾书华吕伟红
Owner CHANGZHOU HI TECH DISTRICT MULTIPLE DIMENSION IND TECH INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap